Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.835 USD | -0.81% | -7.07% | +30.50% |
Financials (USD)
Sales 2024 * | 305K | Sales 2025 * | 7.46M | Capitalization | 128M |
---|---|---|---|---|---|
Net income 2024 * | -64M | Net income 2025 * | -58M | EV / Sales 2024 * | 419 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 17.1 x |
P/E ratio 2024 * |
-1.98
x | P/E ratio 2025 * |
-2.47
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.37% |
Latest transcript on aTyr Pharma, Inc.
1 day | -2.63% | ||
1 week | -0.54% | ||
Current month | +6.94% | ||
1 month | +8.82% | ||
3 months | +13.50% | ||
6 months | +52.89% | ||
Current year | +31.21% |
Managers | Title | Age | Since |
---|---|---|---|
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 16-03-29 |
Jill Broadfoot
DFI | Director of Finance/CFO | 63 | 18-07-29 |
Lisa Carey
CTO | Chief Tech/Sci/R&D Officer | - | 15-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Schimmel
FOU | Founder | 83 | 05-09-07 |
Tim Coughlin
CHM | Chairman | 57 | 17-04-09 |
John Clarke
BRD | Director/Board Member | 70 | 05-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-14 | 1.84 | -0.54% | 99 489 |
24-06-13 | 1.85 | -2.63% | 1,226,114 |
24-06-12 | 1.9 | -2.56% | 189,253 |
24-06-11 | 1.95 | +1.04% | 260,568 |
24-06-10 | 1.93 | -2.53% | 346,353 |
Delayed Quote Nasdaq, June 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.21% | 128M | |
+46.03% | 55.66B | |
-7.53% | 38.98B | |
+36.44% | 38.8B | |
-9.38% | 27.32B | |
+12.31% | 26.29B | |
-16.38% | 20.25B | |
+30.79% | 12.76B | |
+28.57% | 12.18B | |
-0.36% | 12.12B |
- Stock Market
- Equities
- ATYR Stock